Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia

By retrospectively analyzing 288 patients with de novo myelodysplastic syndrome (MDS), we sought to determine the prevalence and clinical characteristics of bone marrow eosinophilia and basophilia that were detected at presentation. Bone marrow eosinophilia and basophilia were defined as a different...

Full description

Saved in:

Bibliographic Details
Published in:	Blood Vol. 101; no. 9; pp. 3386 - 3390
Main Authors:	Matsushima, Takafumi, Handa, Hiroshi, Yokohama, Akihiko, Nagasaki, Jun, Koiso, Hiromi, Kin, Yoshitora, Tanaka, Yoko, Sakura, Tohru, Tsukamoto, Norifumi, Karasawa, Masamitsu, Itoh, Katsuhiko, Hirabayashi, Hisami, Sawamura, Morio, Shinonome, Shogo, Shimano, Shun-ichi, Miyawaki, Shuichi, Nojima, Yoshihisa, Murakami, Hirokazu
Format:	Journal Article
Language:	English
Published:	Washington, DC Elsevier Inc 01-05-2003 The Americain Society of Hematology
Subjects:	Acute Disease Adolescent Adult Aged Aged, 80 and over Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Basophils - pathology Biological and medical sciences Bone Marrow - pathology Bone marrow, stem cells transplantation. Graft versus host reaction Chromosome Aberrations Disease Progression Eosinophilia - epidemiology Eosinophilia - etiology Eosinophilia - pathology Female Hematologic and hematopoietic diseases Humans Japan - epidemiology Leukemia, Myeloid - epidemiology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Leukocyte Count Life Tables Male Medical sciences Middle Aged Myelodysplastic Syndromes - classification Myelodysplastic Syndromes - epidemiology Myelodysplastic Syndromes - genetics Myelodysplastic Syndromes - pathology Prevalence Prognosis Retrospective Studies Severity of Illness Index Survival Analysis Survival Rate Transfusions. Complications. Transfusion reactions. Cell and gene therapy Japan Human Symptomatology Prevalence Bone marrow Malignant hemopathy Epidemiology Eosinophilia Myelodysplastic syndrome Basophilia
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	By retrospectively analyzing 288 patients with de novo myelodysplastic syndrome (MDS), we sought to determine the prevalence and clinical characteristics of bone marrow eosinophilia and basophilia that were detected at presentation. Bone marrow eosinophilia and basophilia were defined as a differential count of each cell type exceeding 5.0% and 1.0%, respectively. Of 288 patients with MDS, 36 (12.5%) fulfilled this criterion for bone marrow eosinophilia (MDS-Eos); 34 patients (11.8%) showed basophilia (MDS-Bas), and 11 (3.8%) satisfied both criteria (MDS-EosBas). The remaining 229 patients had neither eosinophilia nor basophilia in their bone marrow (MDS−/−) at presentation. Cytogenetic analysis was carried out on unstimulated bone marrow cells obtained from 264 patients. When the cytogenetic categorization of the IPSS (International Prognostic Scoring System) for MDS was applied, significantly higher numbers of MDS-Eos and MDS-Bas patients had chromosomal abnormalities carrying intermediate or poor prognosis, compared with the MDS−/− patients. Specific chromosomal abnormalities and complex karyotypes were associated with MDS-Eos and/or MDS-Bas. In accordance with these results, the overall survival rate was significantly lower, and the evolution to acute myelogenous leukemia (AML) occurred more frequently in the MDS-Eos and MDS-Bas than in the MDS−/− patients. Multivariate analysis demonstrated that bone marrow basophilia was an independent risk factor for evolution to AML. Our study indicates that bone marrow eosinophilia and basophilia in patients with MDS predict a poorer prognosis.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	0006-4971 1528-0020
DOI:	10.1182/blood-2002-03-0947